TCTR20170810002招募中3 期
RCT, double-blind study to compare the efficacy used of Co Walk in ACL(anterior cruciate ligament) reconstruction patients, TKR(total knee replacement), and stroke patients.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- RCT
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. patients who sign inform and consent
- •2. age more than 18 years old
- •3. patients who did total knee replacement or anterior cruciate ligament reconstruction
排除标准
- •1. patients who do not want to sign inform consent
- •2. patients who cannot use the machine
研究者
相似试验
已完成
不适用
A randomized controlled double-blind study comparing dexmedetomidine and esmolol effects on Cardiac recovery in patients undergoing valve replacement surgery.PACTR201902822178026menoufia university hospitals120
未知
3 期
Double-blind randomized study to compare the efficacy and safety of tamsulosin prolonged release tablet 0.4 mg with Harnal capsule 0.2 mg in patients with lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH)JPRN-jRCT1080221287Astellas Pharma Inc.400
已完成
不适用
Double-blind randomised controlled study to compare the outcomes of laparoscopic gastric banding and laparoscopic Roux-en-Y gastric bypass in morbidly obese patients attending the Multidisciplinary Morbid Obesity Clinic at King's College Hospitalutritional, Metabolic, Endocrine: ObesityNutritional, Metabolic, EndocrineObesityISRCTN33929407Department of Health
进行中（未招募）
不适用
A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome. - see protocol page 1Patients with type IIb dyslipidemia and features of the metabolic syndrome.EUCTR2004-002408-13-DEFOURNIER Laboratories Ireland Ltd186
进行中（未招募）
不适用
A randomised, double-blind study comparing the efficacy and safety of 145mg NanoCrystal® fenofibrate, 10mg ezetimibe and their combination in patients with type IIb dyslipidemia and features of the metabolic syndrome. - see protocol page 1Patients with type IIb dyslipidemia and features of the metabolic syndrome.EUCTR2004-002408-13-BEFOURNIER Laboratories Ireland Ltd186